New research reveals that people who come off blockbuster slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end conventional lifestyle regimens.
Research printed in a prominent health publication points out that while overweight people often shed substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals using these treatments need to be informed of the danger of fast rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to original weight within about 18 months.
Analyzing Treatments
The research, which reviewed dozens of trials involving over 9,000 of participants, compared the outcomes of these new drugs with older methods.
Researchers emphasize that people who shed pounds through lifestyle changes alone typically have a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Fast Regain
Experts suggest the mode of action of the injections is key to understanding the accelerated rebound.
The injections imitate a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Condition?
Health authorities advise the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, due to the significant potential of weight regain, the therapy might need to be long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
People who have stopped the jabs report a intense return of hunger.
"I experienced a switch activating and you're instantly starving," recalled a patient.
This difficulty is compounded if patients have not developed lasting lifestyle or habit modifications during therapy.
Significant Use
Survey data show that a significant number of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and maintained weight loss likely depends on ongoing behavioural management.
